SITE011-0218

SITE011 (ITA) › SITE011-0218

SITE011-0218

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2026-05-18

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2023-02-28 (study day 93); relationship: not assessed

severe assessed

Grade 1 Alanine aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-02-07 (study day 72); relationship: not assessed

mild assessed

Grade 1 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2023-01-11 (study day 45); relationship: not assessed

mild assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 7); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.